<DOC>
	<DOCNO>NCT02074410</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability pharmacokinetics OMS643762 ( study drug ) subject Huntington 's disease ( HD ) .</brief_summary>
	<brief_title>Safety Efficacy OMS643762 Subjects With Huntington 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>1 . Voluntarily provide informed consent , legally authorize representative ( LAR ) provide inform consent subject assent , accordance local regulation govern Institution Review Board ( IRB ) requirement prior procedure evaluation perform specifically sole purpose study ( Montreal Cognitive Assessment ( MoCA ) ass capacity provide inform consent ) . Capacity provide inform consent determine MoCA investigator judgment accord follow : Subjects score great equal 21 MoCA , judgment investigator , capacity provide valid informed consent , give consent . Subjects score less 21 great equal 18 MoCA , judgment mental health professional ( independent investigator ) capacity provide valid informed consent , may give consent . Subjects score less 21 great equal 18 MoCA , lack capacity give valid inform consent , judgment mental health professional ( independent investigator ) , need LAR provide informed consent assent subject . Subjects score less 18 MoCA LAR provide inform consent assent subject . 2 . Have clinical diagnosis HD , confirm either CAG repeat number great equal 39 positive family history ( first degree relative clinical diagnosis HD ) CAG repeat number know . 3 . Are age great equal 18 less equal 65 year screen visit ( Visit 1 ) . 4 . Have UHDRS Total Functional Capacity great equal 7 Visit 1 . 5 . If currently take antipsychotic medication ( ) , stable regimen least 60 day prior randomization . 6 . Are fluent English . 7 . If female , either ) childbearing potential ( i.e. , surgically sterilize postmenopausal 1 year ) b ) negative pregnancy test sexually active must agree use medically reliable form contraception throughout study . Acceptable method contraception include reliable intrauterine device , hormonal contraception spermicide combination barrier method . 8 . If male , either ) reproductive potential b ) sexually active must agree use medically reliable form contraception throughout study . Acceptable method birth control include spermicide combination barrier method , subject ' female partner willing use medically acceptable method birth control . 9 . Have normal clinical laboratory test result ECG , result minor deviation , consider clinically significant investigator . 1 . Have history presence significant cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological disorder HD , opinion investigator , increase risk study drug may confound interpretation study measure . 2 . Have unstable severe depression , opinion investigator . 3 . Have alcohol drug abuse dependence , define Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision . 4 . Have receive treatment investigational drug device within 60 day prior Visit 1 . 5 . Are pregnant lactating . 6 . Have serum alanine transaminase aspartate transaminase great two time upper limit normal screening . 7 . Have hemoglobin , white blood cell count , absolute neutrophil count , platelet count outside normal range screening . 8 . Are employee Omeros , investigator , study staff member , immediate family member .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>